Resistance mechanisms of tigecycline in Acinetobacter baumannii

Front Cell Infect Microbiol. 2023 May 9:13:1141490. doi: 10.3389/fcimb.2023.1141490. eCollection 2023.

Abstract

Acinetobacter baumannii is widely distributed in nature and in hospital settings and is a common pathogen causing various infectious diseases. Currently, the drug resistance rate of A. baumannii has been persistently high, showing a worryingly high resistance rate to various antibiotics commonly used in clinical practice, which greatly limits antibiotic treatment options. Tigecycline and polymyxins show rapid and effective bactericidal activity against CRAB, and they are both widely considered to be the last clinical line of defense against multidrug resistant A. baumannii. This review focuses with interest on the mechanisms of tigecycline resistance in A. baumannii. With the explosive increase in the incidence of tigecycline-resistant A. baumannii, controlling and treating such resistance events has been considered a global challenge. Accordingly, there is a need to systematically investigate the mechanisms of tigecycline resistance in A. baumannii. Currently, the resistance mechanism of A. baumannii to tigecycline is complex and not completely clear. This article reviews the proposed resistance mechanisms of A. baumannii to tigecycline, with a view to providing references for the rational clinical application of tigecycline and the development of new candidate antibiotics.

Keywords: Acinetobacter baumannii; antibiotic; resistance; resistance mechanism; tigecycline.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter Infections* / drug therapy
  • Acinetobacter baumannii*
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Multiple, Bacterial
  • Humans
  • Microbial Sensitivity Tests
  • Minocycline / pharmacology
  • Minocycline / therapeutic use
  • Tigecycline / pharmacology
  • Tigecycline / therapeutic use

Substances

  • Tigecycline
  • Minocycline
  • Anti-Bacterial Agents

Grants and funding

This work was supported by the National Natural Science Foundation of China. (Grant 32270183 and U22A20338).